Yu Yue, Xu Zhihua, Zhou Hao, Xu Ruyan, Xu Jia, Liu Wenjun, Wu Yuxin, Qiu Yue, Zhang Guangbo, Huang Xue, Chen Yan
Department of General Surgery, The First Affiliated Hospital of Soochow University, NO. 899, Pinghai Road, Suzhou, 215006, China.
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Cancer Cell Int. 2024 Mar 29;24(1):118. doi: 10.1186/s12935-024-03299-0.
Increasing evidence proves that RBP7 plays a significant role in breast cancer (BC). The present study was aimed to investigate the mechanism of RBP7.
Western Blotting and qRT-PCR were performed for evaluating the expression levels. CCK8, colony forming, xenograft mouse model, wound healing and transwell assays were conducted to examine cell ability of proliferation, invasion and migration. Nile red staining and Oil red O staining were used for testing the lipid.
RBP7 was related to overall survival (OS) in patients with HR + BC. RBP7 protein was significantly decreased in HR + BC tissues and cells. RBP7 suppressed HR + BC cell proliferation in vitro and in vivo, and inhibited migration and invasion. RBP7 reduced fatty acid in HR + BC cells by inhibiting the AKT/SREBP1 pathway.
RBP7 may function as a tumor suppressor in HR + BC by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.
越来越多的证据表明视黄醇结合蛋白7（RBP7）在乳腺癌（BC）中发挥重要作用。本研究旨在探讨RBP7的作用机制。
采用蛋白质免疫印迹法（Western Blotting）和实时定量逆转录聚合酶链反应（qRT-PCR）评估表达水平。进行细胞计数试剂盒-8（CCK8）、集落形成、异种移植小鼠模型、伤口愈合和Transwell实验，以检测细胞的增殖、侵袭和迁移能力。采用尼罗红染色和油红O染色检测脂质。
RBP7与激素受体阳性（HR+）乳腺癌患者的总生存期（OS）相关。RBP7蛋白在HR+乳腺癌组织和细胞中显著降低。RBP7在体外和体内均抑制HR+乳腺癌细胞增殖，并抑制其迁移和侵袭。RBP7通过抑制AKT/固醇调节元件结合蛋白1（SREBP1）途径降低HR+乳腺癌细胞中的脂肪酸含量。
RBP7可能通过抑制AKT/SREBP1途径和降低脂肪酸含量，在HR+乳腺癌中发挥肿瘤抑制作用。
Zotero 插件
